Factor VIII Inhibitor Antibodies with C2 Domain Specificity Are Less inhibitory to Factor VIII Complexed with von Willebrand Factor

Summary

In order to clarify the potential role of von Willebrand factor (vWf) in attenuating the inactivation of factor VIII (fVIII) by those antibodies with C2 domain specificity, we investigated a panel of 14 human antibodies to fVIII. Immunoblotting analysis localized light chain (C2 domain) epitopes for four cases, heavy chain (A2 domain) epitopes in five cases, while the remaining five cases were both light and heavy chains. The inhibitor titer was considerably higher for Kogenate, a recombinant fVIII concentrate, than for Haemate P, a fVIII/vWf complex concentrate, in all inhibitor plasmas that had C2 domain specificity. In five inhibitor plasmas with A2 domain specificity and in five with both A2 and C2 domain specificities, Kogenate gave titers similar to or lower than those with Haemate P. The inhibitory effect of IgG of each inhibitor plasma was then compared with recombinant fVIII and its complex with vWf. When compared to the other 10 inhibitor IgGs, IgG concentration, which inhibited 50% of fVIII activity (IC50), was remarkably higher for the fVIII/vWf complex than for fVIII in all the inhibitor IgGs that had C2 domain reactivity. Competition of inhibitor IgG and vWf for fVIII binding was observed in an ELISA system. In 10 inhibitors that had C2 domain reactivity, the dose dependent inhibition of fVIII-vWf complex formation was observed, while, in the group of inhibitors with A2 domain specificity, there was no inhibition of the complex formation except one case. We conclude that a subset of fVIII inhibitors, those that bind to C2 domain determinants, are less inhibitory to fVIII when it is complexed with vWf that binds to overlapping region in the C2 domain.

• References

• 1 Hoyer LW. The factor VIII complex: Structure and function. Blood 1981; 58: 1-13
• 2 Vehar GA, Keyt B, Eaton D, Rodriguez H, O’Brien DP, Rotblat F, Oppermann H, Keck R, Wood WI, Harkins RN, Tuddenham EGD, Lawn RM, Capon DJ. Structure of human factor VIII. Nature 1984; 312: 337-342
• 3 Fay PJ, Haidaris PJ, Smudzin TM. Human factor Villa subunit structure. Reconstitution of factor Villa from the isolated A1/A3-C1-C2 dimer and A2 subunit. J Biol Chem 1991; 266: 8957-8962
• 4 Gill FM. The natural history of factor VIII inhibitors in patients with hemophilia A. In: Factor VIII inhibitors Hoyer LW, editor Alan R. Liss; New York: 1984: 19-29
• 5 Shapiro SS, Hultin M. Acquired inhibitors to the blood coagulation factors. Semin Thromb Haemost 1975; 1: 336-385
• 6 Fulcher CA, Mahoney SdG, Roberts JR, Kasper CK, Zimmerman TS. Localization of human factor VIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci USA 1985; 82: 7728-7732
• 7 Scandella D, Mahoney SdG, Mattingly M, Roeder D, Timmons L, Fulcher CA. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli. Proc Natl Acad Sci USA 1988; 85: 6152-6156
• 8 Scandella D, Mattingly M, de Graaf S, Fulcher CA. Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood 1989; 74: 1618-1626
• 9 Lubahn BC, Ware J, Stafford DW, Reisner HM. Identification of a FVIII epitope recognized by a human hemophilic inhibitor. Blood 1989; 73: 497-499
• 10 Foster PA, Fulcher CA, Houghten RA, Mahoney S de G, Zimmerman TS. A murine monoclonal anti-factor VIII inhibitory antibody and two human factor VIII inhibitors bind to different areas within a twenty amino acid segment of the acidic region of factor VIII heavy chain. Blood Coag Fibrinol 1990; 1: 9-15
• 11 Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost 1992; 67: 665-671
• 12 Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2. Blood 1993; 82: 1767-1775
• 13 Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 1978-1984
• 14 Shima M, Scandella D, Yoshioka A, Nakai H, Tanaka I, Kamisue S, Terada S, Fukui H. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-246
• 15 Shima M, Nakai H, Scandella D, Tanaka I, Sawamoto Y, Kamisue S, Morichika S, Murakami T, Yoshioka A. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor. Br J Haematol 1995; 91: 714-721
• 16 Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A Role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269: 11601-11605
• 17 Andersson L-O, Brown JE. Interaction of factor VUI-von Willebrand factor with phospholipid vesicles. Biochem J 1981; 200: 161-167
• 18 Lajmanovich A, Hudry-Clergeon G, Freyssinet JM, Marguerie G. Human factor VIII procoagulant activity and phospholipid interaction. Biochim Biophys Acta 1981; 678: 1978-1984
• 19 Amano K, Arai M, Koshihara K, Suzuki T, Kagawa K, Nishida Y, Fukutake K. An autoantibody to factor VIII that has less reactivity to factor VUI/von Willebrand factor complex. Am J Hematol 1995; 49: 310-317
• 20 Breckenridge RT, Ratnoff OD. Studies on the nature of the circulating anticoagulant directed against antihemophilic factor: with notes on an assay for antihemophilic factor. Blood 1962; 20: 137-149
• 21 Yorifuji H. Studies on the quantitation of VIII:Ag and the molecular change of FVIII/vWF complex in the process of blood coagulation observed by ELISA using monoclonal antibody. J Tokyo Med Coll 1986; 44: 707-716
• 22 Kasper CK, Aledort LM, Counts RB, Edson JR, Fratantoni J, Green D, Hampton JW, Hilgartner MW, Lazerson J, Levine PH, McMillan CW, Pool JG, Shapiro SS, Shulman NR, Van Eys J. A more uniform measurement of factor VIII inhibitors. Thromb Diath Haemorrh 1975; 34: 869-872
• 23 Weiss HJ, Sussman II, Hoyer LW. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand’s disease. J Clin Invest 1977; 60: 390-404
• 24 Over J, Sixma JJ, Bruine MH, Trieschnigg MC, Vlooswijk RA, Beeser-Visser NH, Bouma BN. Survival of 125 iodine-labeled factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human factor VIII. J Clin Invest 1978; 62: 223-234
• 25 Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read MS. Purified factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci USA 1985; 82: 8752-8756
• 26 Mazurier C, Dieval J, Jorieux S, Delobel J, Goudemand M. A new von Willebrand factor (vWF) defect in a patient with factor VIII (FVIII) deficiency but with normal levels and multimeric patterns of both plasma and platelet vWF: characterization of abnormal vWF/FVIII interaction. Blood 1990; 75: 20-26
• 27 Nishino M, Girma JP, Rothschild C, Fressinaud E, Meyer D. New variant of von Willebrand disease with defective binding to factor VIII. Blood 1989; 74: 1591-1599
• 28 Kaufman RJ, Wasley LC, Dorner AJ. Synthesis, processing and secretion of recombinant human factor VIII expressed in mammalian cells. J Biol Chem 1988; 263: 6352-6362
• 29 Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82: 1236-1243
• 30 Rick ME, Esmon NL, Krizek DM. Factor IXa and von Willebrand factor modify the inactivation of factor VIII by activated protein C. J Lab Clin Med 1990; 115: 415-421
• 31 Koedam JA, Hamer RJ, Beeser-Visser NH, Bouma BN, Sixma JJ. The effect of von Willebrand factor on activation of factor VIII by factor Xa. EurJ Biochem 1990; 189: 229-234
• 32 Hill-Eubanks DC, Lollar P. von Willebrand factor is a cofactor for thrombin-catalyzed cleavage of the factor VIII light chain. J Biol Chem 1990; 265: 17854-17858
• 33 Barrowcliffe TW, Kemball-Cook G, Gray E. Binding to phospholipid protects factor VIII from inactivation by human antibodies. J Lab Clin Med 1983; 101: 34-43
• 34 Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M, Prescott R, Rajalakshmi KJ, Hoyer LW, Saenko E. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86: 1811-1819
• 35 Saenko EL, Scandella D. A mechanism for inhibition of factor VIII binding to phospholipid by von Willebrand factor. J Biol Chem 1995; 270: 13826-13833
• 36 Rizza CR, Biggs R. The treatment of patients who have factor VIII antibodies. Br J Haematol 1973; 24: 65-82
• 37 Austen DEG, Lechner K, Rizza CR, Rhymes IL. A comparison of the Bethesda and New Oxford methods of factor VIII antibody assay. Thromb Haemost 1982; 47: 72-75
• 38 Littlewood JD, Bevan SA, Kemball-Cook G, Evens RJ, Barrowcliffe TW. Variable inactivation of human factor VIII from different sources by human factor VIII inhibitors. Br J Haematol 1991; 77: 535-538